# A Study of SKB518 in Patients With Lung Cancer

Source: https://onco.cc/trials/nct07019675/  
OnCo record `nct07019675` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tislelizumab and Carboplatin in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of SKB518 in Patients With Lung Cancer is a phase 2 interventional study registered as NCT07019675 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 192 participants planned, started 2025-08-29 and due to reach its primary completion in 2027-02-20. Interventions recorded: SKB518, Tislelizumab and Carboplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07019675
- Phase: 2
- Setting: A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SKB518 in Patients With Lung Cancer
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 192

## Sources

- ClinicalTrials.gov NCT07019675: https://clinicaltrials.gov/study/NCT07019675

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07019675.json